Medicilon reports nine-month revenue growth of 44.13%
Regulatory / securities filing · 美迪西 / 巨潮资讯 CNinfo
Source published: · Event / reporting date: 2026-09-30
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What changed
Medicilon reported consolidated revenue of RMB1.215 billion, up 44.13%, and attributable net income of RMB92.0 million for the nine months ended September 30, 2026. The company returned to profit. Its report does not present a conventional positive-base growth rate for attributable earnings. The quarterly filing is unaudited and covers the year-to-date period.
Why it may matter
The preclinical outsourcing recovery merits attention, while margins, cash collection, and order durability will help test whether it can continue.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections